Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate

IND for Non-Engineered Deltacel/KB-GDT to be Submitted in the Second Half of 2022 with Beginning of Clinical Trial Activation Expected by Year-End

Three Additional IND Filings Will Expand the Company’s Pipeline to Five Allogeneic Gamma Delta T-cell Clinical Trials and Three Product Candidates

HOUSTON, TX, USA I Juen 21, 2022 I Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and data mining platform to discover and develop cell therapies with a focus on immuno-oncology, announces a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT.

Kiromic expects to submit its first new investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second half of 2022. The IND will seek to evaluate Deltacel in combination with a standard antitumor modality, with the expected beginning of trial activation by year-end. Deltacel consists of Gamma Delta T-cells (GDT) that are expanded, enriched, and activated through a proprietary method. Kiromic will also pursue INDs for its Procel and Isocel product candidates in combination with a standard antitumor modality in 2023.

These three additional IND filings will expand the Company’s pipeline to five allogeneic GDT clinical trials and three product candidates.

This reprioritization and expansion of Kiromic’s pipeline follows a recently announced sponsored research agreement to generate in vivo preclinical data. The Company believes that, through this agreement, we will be able to efficiently generate data for our GDT allogeneic therapies and other pre-clinical assets to support our anticipated IND filings.

“We are well positioned to prioritize Deltacel/KB-GDT in combination with a standard antitumor modality as our first IND, which we intend to submit to the FDA during the second half of this year with the expected beginning of trial activation by year-end. We believe that this shift both de-risks and accelerates our immediate path forward, enabling us to advance our non-viral, non-engineered product candidate while also reducing costs and mitigating current supply chain headwinds associated with a virus-based approach,” stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma.

“Against the backdrop of a global cancer cell therapy market that’s expected to exceed $33 billion by 2027, Kiromic’s product pipeline now encompasses three additional Gamma Delta T-cell therapeutic candidates, Deltacel, Procel, and Isocel. Each is being developed to target solid tumors – which represent 90% of all cancers – and each is ideally positioned to address unmet medical needs. We look forward to advancing these candidates into the clinic with the goal of providing new treatment options to patients with cancer,” added Mr. Bersani.

These three IND applications will expand Kiromic’s therapeutic pipeline to five allogeneic GDT clinical trials (see accompanying graphic), including:

  1. New IND #1: Deltacel in combination with a standard antitumor modality, with clinical activation expected to begin by the end of the fourth quarter of 2022
  2. New IND #2: Procel in combination with a standard antitumor modality, with clinical activation expected to begin by the end of the second quarter of 2023
  3. ALEXIS – PRO-1 Procel as a monotherapy, with clinical activation expected to begin by the end of second quarter 2023
  4. New IND #3: Isocel in combination with a standard antitumor modality, targeting clinical activation to begin by the end of the fourth quarter of 2023
  5. ALEXIS – ISO-1 Isocel as a monotherapy, targeting clinical activation to begin by the end of the fourth quarter of 2023
Clinical Trial Candidate Target Phase I

 

New IND #1

DeltacelTM ln combination with

standard antitumor modality

Allogeneic, Non-Viral, Non-engineered

off-the-shelf GDT therapy

 

Universal

Non-Engineered

 

Q4 2022

Expected Beginning of
Activation Process for New
IND #1 Clinical Trial

 

New IND #2

Procel™ in combination with

standard antitumor modality

Allogeneic, off-the-shelf, GDT CAR-T therapy

 

PD-L1

 

Q2 2023

Expected Beginning of
Activation Process for New
IND #2 Clinical Trial

 

ALEXIS – PRO-1

Procel™

Allogeneic, off-the-shelf, GDT CAR-T therapy

 

PD-L1

 

Q2 2023

Expected Beginning of
Activation Process for
ALEXIS-PRO-1 Clinical Trial

 

New IND #3

Isocel™ in combination with

standard antitumor modality

Allogeneic, off-the-shelf, GDT CAR-T therapy

 

Isoform of

Mesothelin

 

Q4 2023

Expected Beginning of
Activation Process for New
IND #3 Clinical Trial

 

ALEXIS – ISO-1

Isocel™

Allogeneic, off-the-shelf, GDT CAR-T therapy

 

Isoform of

Mesothelin

Q4 2023

Expected Beginning of
Activation Process for
ALEXIS-ISO-1 Clinical Trial

About Kiromic BioPharma

Kiromic BioPharma is a clinical stage biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication gamma delta allogeneic T cell therapy treatment platform that exploits the natural potency of gamma delta T cells to target solid cancers. Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology therapies through its robust product pipeline, leveraged by DIAMOND® AI, a proprietary target discovery engine where data science meets target identification to dramatically compress the timeline and cost of drug development. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

SOURCE: Kiromic BioPharma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top